← back to search

Nikita Stempniewicz

GlaxoSmithKline (United States) · US
Area of research
Epidemiology · Nephrology
Research interest
Research interests include Herpesvirus Infections and Treatments, Chronic Kidney Disease and Diabetes, Dialysis and Renal Disease Management, and Diabetes Treatment and Management.
h-index
15
citations
1,498
works
55
NIH funding
primary concept
Medicine
email

Recent publications

The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts
Journal of the American Society of Nephrology 2023cited by 71position: middledoi
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study
European Heart Journal 2023cited by 29position: middledoi
Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP
European Journal of Preventive Cardiology 2022cited by 74position: middledoi
Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes
Diabetes Care 2022cited by 61position: middledoi
Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations
Diabetes Care 2021cited by 145position: firstdoi
Albuminuria Testing in Hypertension and Diabetes: An Individual-Participant Data Meta-Analysis in a Global Consortium
Hypertension 2021cited by 138position: middledoi
Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis
Annals of Internal Medicine 2020cited by 324position: middledoi
Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets
EClinicalMedicine 2020cited by 109position: middledoi
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
The Lancet Diabetes & Endocrinology 2019cited by 315position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jesse Fishman · Madrigal Pharmaceuticals (United States)1 papers (2021–2021)Joseph A. Vassalotti · National Kidney Foundation1 papers (2021–2021)Alex R. Chang · Columbia University1 papers (2021–2021)Andrew S. Levey · Tufts Medical Center1 papers (2021–2021)Josef Coresh · Harvard Stem Cell Institute1 papers (2021–2021)Yingying Sang · University of North Carolina Health Care1 papers (2021–2021)Shoshana H. Ballew · Centre de recherche en Epidémiologie et Santé des Populations1 papers (2021–2021)John K. Cuddeback · American Medical Group Association1 papers (2021–2021)Kunihiro Matsushita · New York University1 papers (2021–2021)Elizabeth L. Ciemins · Weyerhauser (Canada)1 papers (2021–2021)Robert A. Bailey · Janssen Scientific Affairs (United States)1 papers (2021–2021)